Femasys (NASDAQ:FEMY) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Femasys (NASDAQ:FEMY) announced its quarterly earnings data on Friday. The company reported $0.00 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.07, reports. Femasys had a negative return on equity of 534.94% and a negative net margin of 812.74%.The business had revenue of $0.42 million during the quarter, compared to the consensus estimate of $0.77 million.

Femasys Price Performance

Shares of FEMY opened at $0.43 on Friday. Femasys has a 12-month low of $0.31 and a 12-month high of $1.14. The business has a 50-day simple moving average of $0.47 and a two-hundred day simple moving average of $0.62. The company has a quick ratio of 2.95, a current ratio of 4.53 and a debt-to-equity ratio of 0.89. The stock has a market cap of $25.96 million, a PE ratio of -1.59 and a beta of -2.26.

Hedge Funds Weigh In On Femasys

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new position in Femasys in the 4th quarter worth about $36,000. Kovack Advisors Inc. acquired a new position in Femasys in the 4th quarter worth about $27,000. State Street Corp increased its holdings in Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares in the last quarter. Jane Street Group LLC acquired a new position in Femasys in the 4th quarter worth about $62,000. Finally, HRT Financial LP acquired a new position in Femasys in the 4th quarter worth about $30,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Lake Street Capital assumed coverage on Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price objective for the company. Wall Street Zen downgraded Femasys from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.50.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.